Research Progress in the Application of Mazdutide in the Obese Population

DOI: 10.12201/bmr.202604.00089

•  

  Abstract: As the first dual agonist targeting both glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors, Mazdutide exerts significant weight loss effects through multiple mechanisms including delayed gastric emptying, enhanced satiety, suppressed appetite, and regulation of energy metabolism. In individuals with simple overweight or obesity, multiple clinical trials have demonstrated that Mazdutide can significantly reduce body weight, waist circumference, and body mass index (BMI), while improving metabolic indicators such as blood glucose, blood lipids, and blood pressure. The weight loss effect is dose-dependent. In populations with obesity and type 2 diabetes, Mazdutide also shows significant dual benefits in weight reduction and glucose lowering, with efficacy superior to some drugs of the same class and a safety profile similar to traditional GLP-1 receptor agonists. Common adverse reactions are mainly gastrointestinal, mostly mild to moderate, and more frequent during the dose escalation phase. Furthermore, clinical studies on Mazdutide in areas such as polycystic ovary syndrome and postoperative adjuvant therapy are underway, demonstrating its broad application potential. Overall, Mazdutide provides an effective and convenient pharmacological option for patients with obesity or overweight, particularly suitable for adults with poor response to lifestyle interventions and accompanying metabolic abnormalities. This article reviews the mechanism of action, pharmacokinetic characteristics, clinical efficacy, and safety profile of Mazdutide.

  Key words: Mazdutide; dual receptor agonist; obesity or overweight; loss weight

  Submit time: 10 April 2026

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• TANG Kan-kai, LIU Feng-qi, CHEN Zhi-dong. Effects of α7 nicotinic acetylcholine receptor agonist on intestinal injury and mitochondrial autophagy in sepsis mice. 2024. doi: 10.12201/bmr.202410.00066

  zhanglei. Progress in the application of dexmedetomidine in anesthesia through nasal administration. 2024. doi: 10.12201/bmr.202409.00057

  Research Progress on the Application of Traditional Chinese Medicine in Bowel Preparation Before Colonoscopy. 2026. doi: 10.12201/bmr.202601.00054

  阮偲琪, Li Xin. Research progress on peroxisome proliferator activated receptor γ and systemic lupus erythematosus. 2025. doi: 10.12201/bmr.202505.00007

  XuHong. Advances in the treatment of osteopenia-seropathic obesity syndrome in the elderly. 2024. doi: 10.12201/bmr.202411.00064

  Wang Qiang. Research progress of Apelin in oral diseases. 2026. doi: 10.12201/bmr.202603.00040

  Yu Xin. Application and research progress of molecular detection techniques in the diagnosis of childhood tuberculosis. 2025. doi: 10.12201/bmr.202506.00029

  qinyanhong, xiongli, liaozilong, chenrilan. . 2026. doi: 10.12201/bmr.202602.00011

  Zhang Xinzhong. Research progress on folate receptor positive circulating tumor cells and the occurrence and development of non-small cell lung cancer. 2025. doi: 10.12201/bmr.202506.00024

  王馨雨, ZHANG Shujuan. Research progress of GLP-2 in non-alcoholic fatty liver disease. 2025. doi: 10.12201/bmr.202502.00018

• ID	Submit time	Number	Download
  1	2026-03-30	10.12201/bmr.202604.00089V1	Download

• Public  Anonymous  To author only Submit Comments